- Không có dữ liệu
Tiếng Việt
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Recently, Lecheng Intelligent Technology (Suzhou) Co., Ltd. (hereinafter referred to as "Lecheng Intelligent") completed a strategic financing round of tens of millions of yuan, which is exclusively invested by Dongfang Fenghai Capital. The financing funds will mainly be used for technology research and development, laboratory construction, and talent recruitment.This is the second round of financ...
Recently, a Japanese research team has developed a vertical deep ultraviolet emitting semiconductor laser device based on AlGaN, which is expected to be applied in laser processing, biotechnology, and medical fields.As is well known, ultraviolet (UV) is an electromagnetic wave with a wavelength range of 100 to 380nm. These wavelengths can be divided into three regions: UV-A (315-380 nm), UV-B (280...
Recently, German company Tongkuai invested 13 million euros to open its headquarters in Southeast Europe in Hungary and jointly established a digital network demonstration factory in the Gothler Business Park. Its business focuses on machine tools for digital manufacturing and laser sales for batteries and other automotive components.Nicola Leibinger Kamm ü ller, CEO of Tongkuai, said, "It is...
In a significant leap in quantum nanophotonics, a team of European and Israeli physicists introduced a new type of polarized cavity and redefined the limits of light confinement. This groundbreaking work was detailed in a study published yesterday in Natural Materials, showcasing an unconventional photon confinement method that overcomes the traditional limitations of nanophotonics.For a long time...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...